No Data
China Approves Jiangsu Lianhuan Pharmaceutical's Heart Failure Treatment Injection
Jiangsu Lianhuan Pharmaceutical (600513.SH): Digoxin injection obtained pharmaceutical registration certificate.
On December 2, GELONGHUI reported that Jiangsu Lianhuan Pharmaceutical (600513.SH) announced that it recently received the 'Pharmaceutical Registration Certificate' approved and issued by the National Medical Products Administration, with the pharmaceutical name: Digoxin Injection. Digoxin Injection can be used to treat adults with mild to moderate heart failure, increase myocardial contractility in pediatric patients with heart failure, and control ventricular rate in patients with atrial fibrillation, atrial flutter with rapid ventricular rates, and supraventricular tachycardia.
Jiangsu Lianhuan Pharmaceutical (600513.SH): Supervisor Wang Chunyuan shareholding 1500 shares.
On November 11, Gelonhui announced that jiangsu lianhuan pharmaceutical (600513.SH) received a notification from the company supervisor, Mr. Wang Chunyuan, who, based on his recognition of the company's long-term investment value, increased his shareholding in the company by a total of 1,500 shares through the secondary market on November 8, 2024, using his own funds.
Improved Earnings Required Before Jiangsu Lianhuan Pharmaceutical Co., Ltd. (SHSE:600513) Stock's 28% Jump Looks Justified
Jiangsu Lianhuan Pharmaceutical Co., Ltd.'s (SHSE:600513) Stock Is Going Strong: Is the Market Following Fundamentals?
Jiangsu Lianhuan Pharmaceutical (600513.SH): The shareholder structure of the controlling shareholder has been adjusted.
Gelonghui November 5th, Jiangsu Lianhuan Pharmaceutical (600513.SH) announced that the company recently received a notification from the company's controlling shareholder, Lianhuan Group, stating that according to the "Lianhuan Group 38% State-owned Equity Transfer Agreement" signed between the Yangzhou State-owned Assets Supervision and Administration Commission and the Development and Reform Group, the Yangzhou State-owned Assets Supervision and Administration Commission transferred its 38% equity stake in Lianhuan Group to the Development and Reform Group without compensation, but the Development and Reform Group only has the dividend rights of the 38% equity stake in Lianhuan Group. The other shareholder rights are exercised and voted on by the Yangzhou State-owned Assets Supervision and Administration Commission. After the implementation of this equity transfer without compensation, the Development and Reform Group indirectly increased its shareholding in Jiangsu Lianhuan Pharmaceutical by 15.16 through
Why Jiangsu Lianhuan Pharmaceutical's (SHSE:600513) Shaky Earnings Are Just The Beginning Of Its Problems
No Data
